Previous close | 332.80 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 26,362,618 |
Market cap | 30.392B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 29.96 |
EPS (TTM) | 0.11 |
Earnings date | 29 Feb 2024 |
Forward dividend & yield | 0.06 (1.82%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 363.53 |
Key Insights Using the 2 Stage Free Cash Flow to Equity, Haleon fair value estimate is UK£2.62 Haleon is estimated to...
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.